Adaptive Biotechnologies Corporation (ADPT)

CIK 0001478320 · Healthcare · Diagnostics and Research

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-07-29) · 99.1
Q1-2026 8-K (2026-05-05) · 99.1
Latest FY-2025 8-K (2026-02-05) · 99.1  |  8-K (2026-01-12) · 99.1 · 99.2
Q3-2025 8-K (2025-11-05) · 99.1
Q2-2025 8-K (2025-08-05) · 99.1
Q1-2025 8-K (2025-05-01) · 99.1
FY-2024 8-K (2025-02-11) · 99.1
Q3-2024 8-K (2024-11-07) · 99.1
Q2-2024 8-K (2024-08-01) · 99.1
Q1-2024 8-K (2024-05-07) · 99.1  |  8-K (2024-04-05) · 99.1
FY-2023 8-K (2024-02-14) · 99.1
Q3-2023 8-K (2023-11-09) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations
Condensed Consolidated Statements of Comprehensive Income (loss) (unaudited)
—
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Shareholders' Equity
Consolidated Statements of Cash Flows
Notes
Accrued Liabilities
—
Commitments and Contingencies
Convertible Senior Notes and Capped Call Transactions
—
Cybersecurity
—
Deferred Revenue
Equity Incentive Plans
Fair Value Measurements
Goodwill and Intangible Assets
—
Income Taxes
—
Insider Trading Arrangements
Investments
Leases
Microsoft Collaboration Agreement
—
Net Income (loss) Per Share Attributable To Adaptive Biotechnologies Corporation Common Shareholders
—
Net Loss Per Share Attributable To Adaptive Biotechnologies Corporation Common Shareholders
Organization and Description of Business
Pay Vs Performance Disclosure
Property and Equipment, Net
—
Restructurings
Retirement Plan
—
Revenue
Revenue Interest Purchase Agreement
Segment Information
Shareholders' Equity
Significant Accounting Policies